

Research & Reviews: Journal of Pharmaceutical Quality Assurance

A Review on Contrast Induced Nephropathy

Srujitha Kandregula^{1*}, Akhila Karri²

¹Department of Pharmaceutics, Vignan Institute of Pharmaceutical Technology, Vishakapatnam, Andhrapradesh

²Department of Biotechnology, Gonna Institute of Information Technology, Vishakapatnam, Andhrapradesh

Review Article

Received: 17/10/2016
Accepted: 24/10/2016
Published: 28/10/2016

*For Correspondence

Srujitha Kandregula,
Department of Pharmaceutics,
Vignan Institute of
Pharmaceutical Technology,
Vishakapatnam, Andhrapradesh.

E-Mail:

Srujikandregula@gmail.com

Keywords: Kidney, mortality,
Contrast nephropathy;
Radiocontrast

INTRODUCTION

Approximately 1.4 million of catheterization techniques are performed in U.S. every year, and more upgraded registered tomography is orchestrated different purposes. For these methods, Contrast Medium (CM) is broadly utilized with either diagnostic (coronary angiography) and helpful (coronary angioplasty) plan, and parenteral organization of iodinated CM is a typical precipitator of Contrast-Induced Nephropathy (CIN) (or Contrast-Induced Acute Kidney Injury [CIAKI]). Expectedly more patients would create CIN with the headway of drug, and right now CIN is now the third most normal reason for doctor's facility procured AKI in registry concentrates on. It is progressively perceived that improvement of CIN predicts lifted danger recently Acute Myocardial Infarction (AMI), longer in-doctor's facility stay, and more confounded hospitalization course, and higher in hospital mortality. Patients with CIN additionally have fundamentally higher in hospital mortality (7-22%) and also 1-year (12-37%) and even 5-year mortality (44-78%) than those without CIN^[1-9].

All the more significantly, balance incited AKI connects with higher human services asset use including hospitalization cost^[10], particularly if such CIN scene is dialysis-requiring. As our insight into the pathogenesis and the hazard elements of CIN grows, these advances help fundamentally in formulating systems to forestall CIN after CM infusion. Therefore, an intensive comprehension of the study of disease transmission, pathophysiology, clinical indications, conclusion, counteractive action methodology and administration of complexity initiated AKI is basic for general therapeutic specialists.

Risk Factors

Hazard components ID is critical for clinicians to diminish the frequency of ailments. Also, recognizable proof of defenseless populaces to CIN before CM presentation is imperative, since appropriate patient arrangement, signs and CM administration course characterization can successfully bring down the danger of CIN. As of now, hazard components for CIN advancement can be isolated into 3 sections: tolerant level, pharmaceutical, and strategy level variables.

Ageing

Propelled age is an essential component that improves the likelihood of creating CIN. The meaning of cutting edge age varies between concentrates, however for the most part a cut-off scope of 65-75 years is settled upon^[13]. Being more established than 75 years can convey a 2-5 overlap higher danger of CIN, and it is assessed that like clockwork addition following 75 years predicts a 2% expanded hazard^[11-20].

Diabetes Mellitus

DM has been set up as an autonomous hazard calculate for CIN. Nearness of DM is connected with a 1.5 ~ 3 overlap higher danger of AKI after CM presentation. Moreover, DM opens up the hazard gave by previous renal inadequacy alone. The components incorporate an inclination of the host kidney to ischemic harm (from vasculopathy), expanded oxidative anxiety/free radical harm, and endothelial brokenness.

Arterial hypotension

Hemodynamic unsteadiness has been cited as a hazard figure for CIN, showing in covariates, for example, hypotension. The systems probably include renal hypoperfusion with resultant renal ischemia^[2,27]. Situation of Intra-Aortic Balloon Pump (IABP) could likewise raise the danger of CIN, through potential blood vessel hypotension, intra-agent elements (entangled and longer systems) and post-agent intricacies (atheroemboli separation)^[5,11,13].

Medication factors

Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs), through their glomerular hemodynamic impact, have been ensnared in inclining patients to CIN, yet not very many studies demonstrate this causality. It shown that ACEI or ARB utilize is connected with 3-overlay higher danger of creating CIN after coronary angiography. Different operators, for example, cyclosporin, tacrolimus, platinum-based chemotherapeutic regimens and aminoglycosides can all be offenders in CIN, however little information exists for such affiliation. In any case, doctors are still encouraged to avoid these drugs, if conceivable, in patients planning for CM introduction. Likewise, utilization of metformin in CIN patients could raise the danger of resulting lactic acidosis, and end of metformin ought to be considered in this setting.

Clinical Course

The standard of CIN is that sCr starts to ascend inside 24 hours after difference medium organization, tops at 3-5 days, and comes back to benchmark level or close gauge inside 1-3 weeks. Most patients creating CIN don't require dialysis, yet they do have poorer short term and long haul survival. It was reported that exclusive 0.4% of patients require hemodialysis after CIN happened, however those requiring dialytic bolster had especially higher mortality (12-35%)^[41-49].

Pathophysiology

The pathophysiologic succession of CIN includes two parts: vasoactive go between related vasoconstriction with resultant renal ischemia; and the immediate tubulotoxicity applied by CM. To start with, CM are fit for modifying renal hemodynamics through their activities on renal vasoactive specialists. The high osmolality of CM could initiate renal blood stream diminishing, and CM essentially additionally upgrade erythrocyte collection. What's more, CM have additionally been accounted for to bring about shunting of blood stream to the renal cortex, prompting to medullary ischemia and tubular root.

Diagnosis

Other quickly responsive serum markers going for prior location of renal capacity change likewise are under scrutiny. Cystatin C is a cationic low atomic weight cysteine protease, uninhibitedly sifted by glomeruli, subsequently serving as a decent marker for evaluating Glomerular Filtration Rate (GFR). A Japanese study found that serum cystatin C estimation after angiography essentially connects with AKI advancement. Cystatin C is especially helpful in patients with diabetic history.

Neutrophil Gelatinase-Associated Lipocalin (NGAL) is a little anxiety protein discharged from harmed tubular cells after different boosts. Numerous studies have recorded great affectability and reasonable specificity in prior identification of AKI. Hirsch et al. initially showed that urinary NGAL predicts balance prompted AKI decently with 73% affectability and 100% specificity, while others likewise achieve comparative conclusions^[50-63].

Other potential biomarkers for difference instigated AKI, incorporate kidney-damage atoms - 1 (KIM-1) and urinary L Type Fatty Acid-Binding Protein (L-FABP), yet couple of human studies are accessible as of now. In any case, a nearby checking of sCr change and different markers of renal capacity change after difference presentation is still essential and important to identify any confirmation of complexity incited nephropathy after PCI^[64-99].

CONCLUSION

Contrast-induced AKI, or contrast-induced nephropathy, is a growing issue in the contemporary field of intervention cardiology and also in fields like diagnostic radiology. Although the definitions of contrast-induced AKI are still changing with the advancement of new biomarkers, the most cost-effective method is still serum creatinine in light of the economic burden encountered in most countries. As the understanding of the pathogenesis of CIN also progresses, more and more strategies for prevention of contrast-induced AKI will be developed and tested clinically. It will be vital for primary care physicians and cardiologist to carefully choose their patients for contrast medium containing procedure and stratify the risk of these patients, to reduce this potentially avoidable complication.

REFERENCES

1. Riley RF, Don CW, Powell W, Maynard C, Dean LS (2011) Trends in coronary revascularization in the United States from 2001 to 2009: recent declines in percutaneous coronary intervention volumes. *Circ Cardiovasc Qual Outcomes* 4: 193-197.
2. McCullough PA (2008) Contrast-induced acute kidney injury. *J Am Coll Cardiol* 51: 1419-1428.
3. Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Palevsky PM, et al. (2008) Incidence and outcomes of contrast-induced AKI following computed tomography. *Clin J Am Soc Nephrol* 3: 1274-1281.
4. Nash K, Hafeez A, Hou S (2002) Hospital-acquired renal insufficiency. *Am J Kidney Dis* 39: 930-936.
5. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, et al. (2005) Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. *Am J Cardiol* 95: 13-19.
6. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, et al. (2004) Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 44: 1780-1785.
7. Barrett BJ (1994) Contrast nephrotoxicity. *J Am Soc Nephrol* 5: 125-137.
8. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW (1997) Acute Renal Failure after Coronary Intervention: Incidence, Risk Factors, and Relationship to Mortality. *Am J Med* 103: 368-75.
9. Weisbord SD, Chen H, Stone RA, Kip KE, Fine MJ, et al. (2006) Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. *J Am Soc Nephrol* 17: 2871-2877.
10. Subramanian S, Tumlin J, Bapat B, Zyczynski T (2007) Economic burden of contrast-induced nephropathy: implications for prevention strategies. *J Med Econ* 10: 119-134.
11. Bartholomew BA, Harjai KJ, Dukkupati S, Boura JA, Yerkey MW, et al. (2004) Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. *Am J Cardiol* 93: 1515-1519.
12. Solomon R, Dauerman HL (2010) Contrast-induced acute kidney injury. *Circulation* 122: 2451-2455.
13. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, et al. (2004) A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol* 44: 1393-1399.
14. Guitterez NV, Diaz A, Timmis GC, O'Neill WW, Stevens MA, et al. (2002) Determinants of serum creatinine trajectory in acute contrast nephropathy. *J Interv Cardiol* 15: 349-354.
15. Morcos SK, Thomsen HS, Webb JA (1999) Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). *Eur Radiol* 9: 1602-1613.
16. Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, et al. (2011) Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. *Eur Radiol* 21: 2527-2541.
17. Kwon SH, Hyun J, Jeon JS, Noh H, Han DC (2011) Subtle change of cystatin C, with or without acute kidney injury, associated with increased mortality in the intensive care unit. *J Crit Care* 26: 566-571.
18. Cruz DN, Ricci Z, Ronco C (2009) Clinical review: RIFLE and AKIN--time for reappraisal. *Crit Care* 13: 211.
19. Molitoris BA, Levin A, Warnock DG, Joannidis M, Mehta RL, et al. (2007) Improving outcomes of acute kidney injury: report of an initiative. *Nat Clin Pract Nephrol* 3: 439-442.
20. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, et al. (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation* 105: 2259-2264.

21. Anderson S, Eldadah B, Halter JB, Hazzard WR, Himmelfarb J, et al. (2011) Acute kidney injury in older adults. *J Am Soc Nephrol* 22: 28-38.
22. Chao CT, Wu VC, Lai CF, Shiao CC, Huang TM, et al. (2012) Advanced age affects the outcome-predictive power of RIFLE classification in geriatric patients with acute kidney injury. *Kidney Int* 82: 920-927.
23. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, et al. (2008) Hyperglycemia and Acute Coronary Syndrome: A scientific statement from the american heart association diabetes committee of the council on nutrition, physical activity, and metabolism. *Circulation* 117: 1610-1619.
24. Hoste EA, Doom S, De Waele J, Delrue LJ, Defreyne L, et al. (2011) Epidemiology of contrast-associated acute kidney injury in ICU patients: a retrospective cohort analysis. *Intensive Care Med* 37: 1921-1931.
25. Stolker JM, McCullough PA, Rao S, Inzucchi SE, Spertus JA, et al. (2010) Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. *J Am Coll Cardiol* 55: 1433-1440.
26. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, et al. (1989) Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. *New Engl J Med* 320: 143-149.
27. Goldenberg I, Matetzky S (2005) Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. *CMAJ* 172: 1461-1471.
28. Glasscock RJ, Winearls C (2008) The global burden of chronic kidney disease: how valid are the estimates? *Nephron Clin Pract* 110: c39-46.
29. Delanaye P, Cohen EP (2008) Formula-based estimates of the GFR: equations variable and uncertain. *Nephron Clin Pract* 110: c48-53.
30. Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, et al. (2001) Acute renal failure requiring dialysis after percutaneous coronary interventions. *Catheter Cardiovasc Interv* 52: 409-416.
31. Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, et al. (2005) Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. *Kidney Int* 67: 706-713.
32. Krumlovsky FA, Simon N, Santhanam S, del Greco F, Roxe D, et al. (1978) Acute renal failure. Association with administration of radiographic contrast material. *JAMA* 239: 125-127.
33. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, et al. (2006) Risk Prediction of Contrast-Induced Nephropathy. *Am J Cardiol* 98: 27-36.
34. Yoshioka T, Fogo A, Beckman JK (1992) Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. *Kidney Int* 41: 1008-1015.
35. Umrudin Z, Moe K, Superdock K (2012) ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy. *J Nephrol* 25: 776-781.
36. Thomsen HS, Morcos SK (2009) Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT-a pooled analysis of two randomized trials. *Eur Radiol* 19: 891-897.
37. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, et al. (2006) Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction. *Circulation* 113: 2906-2913.
38. Diogo LP, Saitovitch D, Biehl M, Bahlis LF, Guterres MC, et al. (2010) Is there an association between non-steroidal anti-inflammatory drugs and contrast nephropathy? *Arq Bras Cardiol* 95: 726-731.
39. Kitajima K, Maeda T, Watanabe S, Sugimura K (2011) Recent issues in contrast-induced nephropathy. *Int J Urol* 18: 686-690.
40. Barrett BJ, Carlisle EJ (1993) Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. *Radiology* 188: 171-178.
41. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, et al. (2003) Nephrotoxic effects in high-risk patients undergoing angiography. *N Engl J Med* 348: 491-499.
42. Chalmers N, Jackson RW (1999) Comparison of iodixanol and iohexol in renal impairment. *Br J Radiol* 72: 701-703.
43. McCullough PA, Bertrand ME, Brinker JA, Stacul F (2006) A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. *J Am Coll Cardiol* 48: 692-699.
44. Solomon R (2005) The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. *Kidney Int* 68: 2256-2263.

45. Lindsay J, Apple S, Pinnow EE, Gevorkian N, Gruberg L, et al. (2003) Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. *Catheter Cardiovasc Interv* 59: 338-343.
46. Manske CL, Sprafka JM, Strony JT, Wang Y (1990) Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. *Am J Med* 89: 615-620.
47. Cigarroa RG, Lange RA, Williams RH, Hillis LD (1989) Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. *Am J Med* 86: 649-652.
48. Moore RD, Steinberg EP, Powe NR, Brinker JA, Fishman EK, et al. (1992) Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. *Radiology* 182: 649-655.
49. McCullough PA, Sandberg KR (2003) Epidemiology of contrast-induced nephropathy. *Rev Cardiovasc Med* 4: S3-9.
50. Nygren A, Ulfendahl HR (1989) Effects of high- and low-osmolar contrast media on renal plasma flow and glomerular filtration rate in euvoaemic and dehydrated rats. A comparison between ioxithalamate, iopamidol, iohexol and ioxaglate. *Acta Radiol* 30: 383-389.
51. Liss P, Nygren A, Olsson U, Ulfendahl HR, Erikson U (1996) Effects of contrast media and mannitol on renal medullary blood flow and red cell aggregation in the rat kidney. *Kidney Int* 49: 1268-1275.
52. Heyman SN, Brezis M, Epstein FH, Spokes K, Silva P, et al. (1991) Early renal medullary hypoxic injury from radiocontrast and indomethacin. *Kidney Int* 40: 632-642.
53. Ueda J, Nygren A, Hansell P, Ulfendahl HR (1993) Effect of intravenous contrast media on proximal and distal tubular hydrostatic pressure in the rat kidney. *Acta Radiol* 34: 83-87.
54. Jacobsson B, Lignelid H, Bergerheim US (1995) Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. *Histopathology* 26: 559-564.
55. Inker LA, Okparavero A (2011) Cystatin C as a marker of glomerular filtration rate: prospects and limitations. *Curr Opin Nephrol Hypertens* 20: 631-639.
56. Takeuchi T, Isobe S, Sato K, Kato MI, Kasai NN, et al. (2011) Cystatin C: a possible sensitive marker for detecting potential kidney injury after computed tomography coronary angiography. *J Comput Assist Tomogr* 35: 240-245.
57. Ribichini F, Gambaro G, Graziani MS, Pighi M, Pesarini G, et al. (2012) Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions. *Clin Chem* 58: 458-464.
58. Bolignano D, Coppolino G, Lacquaniti A, Buemi M (2010) From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. *Eur J Clin Invest* 40: 273-276.
59. Chen TH, Chang CH, Lin CY, Jenq CC, Chang MY, et al. (2012) Acute kidney injury biomarkers for patients in a coronary care unit: a prospective cohort study. *PLoS One* 7: e32328.
60. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A; NGAL Meta-analysis Investigator Group (2009) Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis* 54: 1012-1024.
61. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, et al. (2005) Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. *Lancet* 365: 1231-1238.
62. Hirsch R, Dent C, Pfrim H, Allen J, Beekman RH 3rd, et al. (2007) NGAL is an early predictive biomarker of contrast-induced nephropathy in children. *Pediatr Nephrol* 22: 2089-2095.
63. Schilcher G, Ribitsch W, Otto R, Portugaller RH, Quehenberger F, et al. (2011) Early detection and intervention using neutrophil gelatinase-associated lipocalin (NGAL) may improve renal outcome of acute contrast media induced nephropathy: A randomized controlled trial in patients undergoing intra-arterial angiography (ANTI-CIN Study). *BMC Nephrol* 12: 39.
64. Malyszko J (2010) Biomarkers of acute kidney injury in different clinical settings: a time to change the paradigm? *Kidney Blood Press Res* 33: 368-382.
65. Erselcan T, Egilmez H, Hasbek Z, Tandogan I (2012) Contrast-induced nephropathy: controlled study by differential GFR measurement in hospitalized patients. *Acta Radiol* 53: 228-232.
66. Esposito T, Napoleone A, Allocca S, Varriale B, Monda M (2014) Diet Therapy of Obesity: Observations on the Usefulness of Weekly Supervision in the Improvement of Weight Loss. *J Obes Weight Loss Ther* 4:225.

67. Margarida Moreira (2015) Excessive Weight Gain in Pregnancy and Postpartum Weight Retention: a Comprehensive View on the Topic. *Clinics Mother Child Health* 12:186.
68. Buyuktuncer Z, Koksal G, Dagdelen S, Ozdemir P, Isildak M, et al. (2015) Weight Gain under Stress. *Endocrinol Metab Syndr* 4:202.
69. Malavolti M, Petrella E, Bertarini V, Dietitian, Cicchetti C, et al. (2016) Gestational Weight Gain and Changes in Body Composition in Pregnant Women with BMI ≥ 25 Kg/m² Undergoing a Healthy Lifestyle Program Starting Early in Pregnancy. *J Obes Weight Loss Ther* 6:300.
70. Eapen V, Brac GF, Ward P, Hazell P, Barton G, et al. (2012) Evaluation of Weight Gain and Metabolic Parameters among Adolescent Psychiatric Inpatients Role of Health Promotion and Life Style Intervention Programs. *J Metabolic Syndr* 1:109.
71. Nguyen ML, Shapiro MA, Rahmani M (2012) Zonisamide for Attenuation of Weight Gain in a Morbidly-Obese Adolescent on an Antipsychotic. *J Obes Wt Loss Ther* 2:134.
72. Pierrefiche O, Daoust M, Naassila M (2016) Use of Alcohol during Pregnancy in France: Another French Paradox?. *J Preg Child Health* 3:246.
73. Nodine PM, Leiferman JA, Cook PF, Matthews E, Tolsma MH (2016) The Impact of Physical Activity on Sleep during Pregnancy: A Secondary Analysis. *Clinics Mother Child Health* 13:245.
74. Bozhkov AI, Nikitchenko Yu V, Al-Bahadly Ali MM (2016) Overeating in Early Postnatal Ontogenesis Forms Metabolic Memory and Reduces Lifespan. *J Gerontol Geriatr Res* 5: 309.
75. Yarnell S, Oscar-Berman M, Avena NM, Blum K, Gold MS (2013) Pharmacotherapies for Overeating and Obesity. *J Genet Syndr Gene Ther* 4:131.
76. Sur A, Tirkey BN, Mishra PK (2015) Evaluation of Role of Serum Lipoprotein and Lipid Profile in Essential Hypertension Patients in a Tertiary Care Hospital. *J Hypertens* 4:204.
77. Tsabang N, Yedjou CG, Tsambang LWD, Tchinda AT, Donfagsiteli N, et al. (2015) Treatment of Diabetes and/or Hypertension Using Medicinal Plants in Cameroon. *Med Aromat Plants* S2:003.
78. Ashoor I (2015) Pediatric Hypertension: A Primer for the Busy Primary Care Provider. *J Nephrol Ther* 5:218.
79. Bos AJG, Jorge LB, Navarro JHN, Gerlack LF, Rocha JP, et al. (2015) Comparing the Prevalence and Drug Treatment Rates of Diabetes, Hypertension and Dyslipidemia between Japan and Brazil, using 2013 National Health Surveys. *J Clin Diabetes Pract* 1:103.
80. Mussa BM, Abdullah Y, Abusnana S (2016) Prevalence of Hypertension and Obesity among Emirati Patients with Type 2 Diabetes. *J Diabetes Metab* 7:638.
81. Feyh A, Bracero L, Lakhani HV, Santhanam P, Shapiro JI, et al. (2016) Role of Dietary Components in Modulating Hypertension. *J Clin Exp Cardiol* 7:433.
82. Li M, Zhang L, Shi J (2016) To Live Long, Eat Less Salt: Salt Intake Reduction Promotion and Hypertension Control in China. *Health Care: Current Reviews* 4:169.
83. Chauhan R, Parihar AKS, Chauhan S (2016) Hypertension and the Aged. *J Gerontol Geriatr Res* S5:002.
84. Ozdag Y, Didem Suna Y, Yavuz B (2015) An Assessment of the Awareness of Lifestyle Changes in Patients with Hypertension. *Fam Med Med Sci Res* 4: 178.
85. Miller GD, Hale E, Dunlap G (2015) Current Evidence for Physical Activity in the Bariatric Surgery Patient for Weight Loss Success. *J Obes Weight Loss Ther* 5: 274.
86. Bernante P (2015) The Impact of Obesity and Weight Loss on Patients with Systemic Lupus Erythematosus: Is There a Role for Bariatric Surgery?. *Rheumatology (Sunnyvale)* 5: 145.
87. Aldeen T, Adewale A (2015) Obesity and Psoriasis: Can Bariatric Surgery Trigger Psoriasis?. *J Clin Exp Dermatol Res* 6: 302.
88. Abiad F, Abbas HA, Hamadi C, Ghazeeri G (2016) Bariatric Surgery in the Management of Adolescent and Adult Obese Patients with Polycystic Ovarian Syndrome. *J Obes Weight Loss Ther* 6: 303.
89. Livadariu RM, Timofte D, Ionescu L, Dănilă R, Drug V, et al. Upper Digestive Endoscopy Prior to Bariatric Surgery in Morbidly Obese Patients - A Retrospective Analysis. *Journal of Surgery [Jurnalul de chirurgie]*. 2016; 12: 19-21.
90. Nielsen S, Svane MS, Bojsen-Møller KN, Madsbad S (2014) Effects of Bariatric Surgery on Weight Loss and Quality of Life. *Anaplastology* 3:136.
91. Parkyn WR, Chan CY, Van Rij AM (2014) Skin Problems in the Lower Legs of Morbidly Obese Patients and the Possible Role of Bariatric Surgery. *J Obes Weight Loss Ther* 4: 230.

92. Lier HØ, Biringer E, Bjørkvik J, Rosenvinge JH, Stubhaug B, et al. (2012) Shame, Psychiatric Disorders and Health Promoting Life Style after Bariatric Surgery. *J Obes Weig los Ther* 2:113.
93. Hardeman W, Sutton S, Griffin S, et al. A causal modelling approach to the development of theory-based behaviour change programmes for trial evaluation. *Health Educ. Res* (2005); Pp: 676-687.
94. Neville LM, O'Hara B, Milat AJ (2009) Computer-tailored dietary behaviour change interventions: a systematic review. *Health Educ. Res* 24: 699-720.
95. Susan Michie (2008) Designing and implementing behaviour change interventions to improve population health. *J Health Serv Res Policy* 13: 64-69.
96. Armstrong D, Reyburn H, Jones R, Wolfson (1996) A study of general practitioners' reasons for changing their prescribing behaviour. *BMJ* 312: 949.
97. Miles A, Rapoport L, Wardle J, Afuape T, Duman M, et al. (2001) Using the mass-media to target obesity: an analysis of the characteristics and reported behaviour change of participants in the BBC's 'Fighting Fat, Fighting Fit' campaign. *Health Educ. Res* 16: 357-372.
98. Cameron R, MacDonald MA, Schlegel RP, Young CI, Fisher SE, et al. (1990) Toward the development of self-help health behaviour change programs: weight loss by correspondence. *Europe PMC* 81: 275-279.
99. Burke V, Beilin L J, Cutt HE, Mansour J, Mori TA, et al. (2007) Moderators and mediators of behaviour change in a lifestyle program for treated hypertensives: a randomized controlled trial (ADAPT). *Health Educ. Res* 23: 583-591.